AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$LQDA

Adair Jason sold $5.1M of LQDA

Adair Jason (Chief Business Officer) sold 73,631 shares of Liquidia Corp (LQDA) at $69.09 ($5.09M total) across 2 trades on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Adair Jason
Published Aug 25, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as reduced confidence.

02

Market read

Insider sales of this size from a C‑suite officer are noteworthy for traders monitoring biotech stocks.

03

What to watch

Upcoming clinical trial data could offset selling pressure if results are positive.

Relevance 5/10Novelty 7/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Business Officer sold 73,631 shares for $5.1M via a 10b5‑1 plan, reducing his stake to 174,606 shares.

Expected impact

Modest downward pressure over the next few days.

Evidence & confidence

C‑suite insider selling $5M is material for a mid‑cap biotech; market often reacts negatively to such sales.

Market effects

Sector

May raise questions about insider confidence in the biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Liquidia Corp

    Biotech firm developing drug delivery platforms.

  • Person
    Adair Jason

    Chief Business Officer of Liquidia Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

OCT 20
$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

news.alphastreet.com1 min
OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min